Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM512 Injection in Subjects With Moderate-to-severe Asthma.
NCT07011524 is registered in ClinicalTrials.gov with Keymed Biosciences Co.Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM512 Injection in Subjects With Moderate-to-severe Asthma.
- Lead sponsor
- Keymed Biosciences Co.Ltd
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 19, 2025
- Completion date
- July 21, 2027
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.